Communication gaps between patients with breast cancer, caregivers, oncology care team
the ONA take:
Survey results presented at the 37th Annual San Antonio Breast Cancer Symposium reveal that discussions on basic disease information between patients with metastatic breast cancer, their caregivers, and oncologists need improvement.
The “Make your dialogue count” survey was conducted from June 2014 through August 2014. It was developed to gain insight from adult women ages 21 years and older with metastatic breast cancer, adult caregivers of these patients who attend at least half the patients’ clinic visits, and medical oncologists who treat five or more women with metastatic breast cancer per month.
Survey results indicate most patients (83%) and caregivers (76%) are extremely or very involved in treatment decisions; however, many patients and caregivers did not know the HER2 status (20% and 29%, respectively) or the HR status (16% and 30%, respectively).
In addition, 27% of oncologists indicated that they do not discuss the fact that metastatic breast cancer is incurable with patients in certain circumstances.
Most patients (73%) want more information on preventing and minimizing side effects; however, 43% of patients do not always openly discuss side effects with their oncologists. The investigators conclude that improved dialogue can clarify patients’ and caregivers’ expectations about disease management.
Discussions on basic disease information between patients with metastatic breast cancer, caregivers, and oncologists.
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Clinical Trials May Benefit Oncology Patients
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|